Gene Expression Profiles in Muscle After Immunisation

Not Applicable

Completed

• Conditions: Healthy
• Interventions: Biological: Placebo; Biological: Fendrix; Biological: Fluad

• Registration Number: NCT02368327
• Lead Sponsor: University of Surrey

Brief Summary

This clinical study is part of the BIOVACSAFE project which is funded by the Innovative Medicine Initiative. In this study we will take a small muscle biopsy in order to identify any differences in the response around the actual site of injection compared with responses we measure in blood at the same time.

Detailed Description

Not available

Study Timeline

• Status Verified: 2015-02
• Study Start: 2015-02
• Study First Submitted: 2015-02-13
• Study First Submitted QC: 2015-02-13
• Study First Posted: 2015-02-23
• Primary Completion: 2015-07
• Study Completion: 2015-07
• Last Update Submitted: 2015-08-07
• Last Update Posted: 2015-08-10

Recruitment & Eligibility

• Status: COMPLETED
• Sex: Male
• Target Recruitment: 45

Inclusion Criteria

1. The participant is able to read and understand the Informed Consent Form (ICF), and understand study procedures.
2. The participant has signed the ICF.
3. Healthy male participants aged 18-45 years inclusive.
4. BMI between 19-27 kg/m2.
5. Pre-immunised with Hepatitis B vaccine
6. Hepatitis B sAb positive (evidence of vaccine-induced immunity)
7. Hepatitis B sAg and cAb negative (evidence of lack of prior/current HBV infection)
8. Hepatitis C and HIV seronegative.
9. Available for follow-up for the duration of the study.
10. Agree to abstain from donating blood during the study.
11. The participant is, in the opinion of the investigator, healthy on the basis of a, medical history, a symptom directed medical examination and vital signs.

Exclusion Criteria

1. History of hypersensitivity to any of the vaccine components or a history of any allergy that in the opinion of the investigator would contraindicate participant participation
2. Clinically significant psychiatric, cardiovascular, respiratory, hepatic, renal, gastrointestinal, endocrine, neurological (particularly myasthenia gravis), immunological, or haematological disease or abnormality, as determined by the study physician.
3. Known immune or coagulation disorder or clinically significant abnormalities of platelets, Hb or coagulation on screening labs
4. Known allergy to injected local anaesthetics
5. Unwilling to undergo muscle biopsies
6. Use of steroids or immunosuppressive/immunomodulating drugs either orally or parenterally within 3 months of visit 1.
7. Currently participating in a clinical trial with an investigational or non- investigational drug or device, or has participated in another clinical trial within the 3 months preceding the study.
8. Any condition that, in the investigator's opinion, compromises the participant's ability to meet protocol requirements or to complete the study.
9. Receipt of blood products or immunoglobin, within 3 months of visit 1.
10. Unable to read and speak English to a fluency level adequate for the full comprehension of procedures required in participation and consent.

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: PARALLEL

Arm && Interventions

Group	Intervention	Description
Placebo	Placebo	Participants receive one dose of saline placebo
Fendrix	Fendrix	Participants receive one dose of Fendrix vaccine
Fluad	Fluad	Participants receive one dose of Fluad vaccine

Primary Outcome Measures

Name	Time	Method
Change from baseline values of gene expression in whole blood and muscle	Day 0, Day 0+3 hours, Day 1, Day 3, Day 5 and Day 7

Trial Locations

Locations (1)

Surrey Clinical Research Centre; 🇬🇧 Guildford, Surrey, United Kingdom